Literature DB >> 23957516

Optimal timing for interim analyses in clinical trials.

Kanae Togo1, Manabu Iwasaki.   

Abstract

In clinical trials, interim analyses are often performed before the completion of the trial. The intention is to possibly terminate the trial early or adjust the sample size. The time of conducting an interim analysis affects the probability of the early termination and the number of subjects enrolled until the interim analysis. This influences the expected total number of subjects. In this study, we examine the optimal time for conducting interim analyses with a view to minimizing the expected total sample size. It is found that regardless of the effect size, the optimal time of one interim analysis for the early termination is approximately two-thirds of the planned observations for the O'Brien-Fleming type of spending function and approximately half of the planned observations for the Pocock type when the subject enrollment is halted for the interim analysis. When the subject enrollment is continuous throughout the trial, the optimal time for the interim analysis varies according to the follow-up duration. We also consider the time for one interim analysis including the sample size adjustment in terms of minimizing the expected total sample size.

Mesh:

Year:  2013        PMID: 23957516     DOI: 10.1080/10543406.2013.813522

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  7 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

Review 2.  The principle of equipoise in pediatric drug trials.

Authors:  Kim Chau; Gideon Koren
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

3.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

4.  Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.

Authors:  Ryuji Uozumi; Shinjo Yada; Atsushi Kawaguchi
Journal:  BMC Med Res Methodol       Date:  2019-07-22       Impact factor: 4.615

5.  Do we need to adjust for interim analyses in a Bayesian adaptive trial design?

Authors:  Elizabeth G Ryan; Kristian Brock; Simon Gates; Daniel Slade
Journal:  BMC Med Res Methodol       Date:  2020-06-10       Impact factor: 4.615

6.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

7.  Interim analysis for binary outcome trials with a long fixed follow-up time and repeated outcome assessments at pre-specified times.

Authors:  Sameer Parpia; Jim A Julian; Chushu Gu; Lehana Thabane; Mark N Levine
Journal:  Springerplus       Date:  2014-06-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.